NTLA Q2 2021 Earnings — Intellia Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

NTLAIntellia Therapeutics, Inc.

$2B

Q2 2021 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$7M-59.7% YoY

Gross Profit

-$52M-799.0% margin

Operating Income

-$69M-1053.7% margin

Net Income

-$69M-1050.5% margin

EPS (Diluted)

$-1.01

QoQ Revenue Growth

+1.6%

Cash Flow

Operating Cash Flow

-$53M

Free Cash Flow

-$56M

Stock-Based Comp.

$11M

Balance Sheet

Total Assets

$672M

Total Liabilities

$177M

Stockholders' Equity

$495M

Cash & Equivalents

$130M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$7M	$16M	-59.7%
Gross Profit	-$52M	-$22M	-143.3%
Operating Income	-$69M	-$33M	-108.9%
Net Income	-$69M	-$32M	-112.4%